Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 23 December 2025 - 25 December 2025

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck shares closed at $106.45 on Dec. 24, capping a six-day rally driven by a BMO Capital Markets upgrade to Outperform and a new $130 price target. Analysts cited confidence in Merck’s pipeline as it prepares for Keytruda’s 2028 loss of exclusivity. Recent gains also follow positive oncology data and a European regulatory milestone for Winrevair. U.S. markets were closed Dec. 25 for Christmas.
25 December 2025
·
Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

The U.S. FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP-1 drug for chronic weight management, on Dec. 22. Novo Nordisk ADRs closed at $52.56 on Dec. 24, up 1.8% after the news. The company plans a U.S. launch in early January 2026. Trial data showed a mean weight loss of 16.6% for patients adhering to the regimen.
25 December 2025
·
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck shares hit a 52-week high near $106.50 on December 24 after a six-day, 8.3% rally. The surge followed a BMO Capital Markets upgrade to “Outperform” with a $130 target and positive late-stage trial results for Keytruda combinations in bladder cancer. European regulators advanced WINREVAIR for pulmonary hypertension. U.S. markets were closed December 25.
25 December 2025
··
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer shares traded near $25 on Dec. 24, 2025, valuing the company at about $142 billion amid thin holiday trading. The company’s 2026 guidance, released Dec. 16, projects revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with growth not expected to rebound until later in the decade. Investors remain focused on drug pricing risks, pipeline progress, and looming patent expirations.
24 December 2025
···
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

China’s NMPA approved Zai Lab’s COBENFY for adult schizophrenia on Dec. 23, triggering a surge in Zai Lab shares. The U.S. ADR traded around $18.54 intraday, while Hong Kong shares closed at HK$14.48, up 6.24%. COBENFY is the first M1/M4 muscarinic receptor therapy for schizophrenia approved in China. Zai Lab holds exclusive commercialization rights in Greater China.
24 December 2025
···
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck shares hit a 12-month high near $106 on December 24, 2025, capping a 30% rally over three months. The surge follows a Trump administration deal requiring Merck to cut prices on drugs like Januvia for Medicaid and direct-to-consumer sales. Analysts cite optimism about Merck’s growth beyond Keytruda’s patent expiration and progress on new drugs.
24 December 2025
··
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson traded near $207 per share in thin holiday trading Wednesday, keeping its market value around $500 billion. A Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest such verdict to date. J&J said it will appeal. U.S. markets close early at 1 p.m. ET for Christmas Eve.
24 December 2025
···
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals shares traded near $4.37 on December 24, 2025, after J.P. Morgan upgraded the stock and Cathie Wood’s ARK funds increased their position. Trading volume was in the low millions during the early-close Christmas Eve session. The moves follow positive clinical data from REC-4881’s Phase 1b/2 trial in FAP. RXRX’s market cap stands at roughly $2.12 billion.
24 December 2025
·
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

U.S. regulators have approved Novo Nordisk’s oral Wegovy pill for weight management and cardiovascular risk reduction, sending NVO shares higher earlier this week. Analysts are watching pricing and insurance coverage in the U.S., as well as competition in India ahead of 2026 generic launches. The pill is expected to reach U.S. patients in January. NVO stock traded in the low-$50s on Dec. 24.
24 December 2025
···
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva shares closed at $31.54 on Dec. 23, up 28% since Nov. 5, after S&P Global Ratings upgraded the company’s credit to ‘BB+’ on improved deleveraging. The stock traded near $31.93 pre-market Dec. 24. Analysts, including Piper Sandler, have raised price targets as Teva’s pipeline and biosimilars schedule gains clarity. Investors remain alert to pricing and patent risks.
24 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck (MRK) Stock News and Forecasts for Dec. 23, 2025: TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Wall Street’s Latest Targets

Merck shares traded near $104.68 midday Tuesday, little changed after the company joined TrumpRx drug-pricing agreements offering tariff relief in exchange for lower prices on Medicaid and some cash-pay drugs. Merck will provide Januvia and Janumet at about 70% off list price to eligible U.S. patients. Investors are weighing policy clarity and late-stage pipeline prospects as Keytruda nears loss of exclusivity.
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

U.S. regulators approved Novo Nordisk’s once-daily oral Wegovy pill for chronic weight management and cardiovascular risk reduction on Dec. 23, 2025. Novo shares rose about 9% in U.S. trading, with investors reacting to the company’s first-to-market status for a high-efficacy oral GLP-1 obesity drug. The FDA decision also lifted European healthcare stocks, pushing the STOXX 600 to a record high.
23 December 2025
·
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer shares traded near $25.15 on Dec. 23 after a fatal thrombotic stroke was reported in a patient on its hemophilia therapy Hympavzi, prompting scrutiny from advocacy groups. The company also issued 2026 guidance projecting revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, below analyst expectations.
23 December 2025
···
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management in the U.S., marking the first oral GLP-1 agonist cleared for this use. Shares jumped on the news, lifting European healthcare stocks. The company reported 16.6% mean weight loss in trials when taken as prescribed. Novo plans to launch the pill in the U.S. in early January 2026.
23 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb (BMY) Stock After Hours Today, Dec. 22, 2025: What to Know Before the Market Opens Tuesday

Bristol-Myers Squibb closed at $54.66 Monday, up 0.87%, and traded near $54.75 after hours. Investors are watching the company’s new agreement with the Trump administration, which includes providing Eliquis free to Medicaid from 2026 and donating active pharmaceutical ingredients. The deal grants BMS three years of tariff relief, with further pricing terms kept confidential.
23 December 2025
··
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals closed up 1.87% at $407.73 Monday, its first session as a Nasdaq-100 constituent. The stock slipped 0.12% after hours. Index inclusion drove trading volume to about 1.05 million shares. Alnylam recently announced a $250 million expansion of its Massachusetts manufacturing site.
23 December 2025
···
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

The FDA approved Novo Nordisk’s once-daily Wegovy pill (oral semaglutide 25 mg) for chronic weight management and reducing cardiovascular risk in adults with obesity or overweight on December 22, 2025. The company plans a U.S. launch in January 2026 at $149 per month for eligible patients. Clinical trials showed average weight loss of 13.6% to 16.6% depending on adherence.
23 December 2025
··
1 … 22 23 24 25 26 … 38

Stock Market Today

  • Dow, S&P 500, Nasdaq futures dip as financial sector stumbles on private credit risks
    April 11, 2026, 10:02 AM EDT. Dow, S&P 500, and Nasdaq futures edged lower as the financial sector suffered heavy losses, led by insurance stocks. Shares of Ares, Arthur J. Gallagher, Aon, and Willis Towers Watson dropped after a report from rating firm A.M. Best warned of growing risks tied to private credit in insurers' balance sheets. The report highlighted vulnerabilities in annuity products, which now often rely on lower-quality, less transparent issuers, including overseas affiliates. It noted a surge in private equity-backed insurers entering the annuity market, attracted by the spread between premia inflows and crediting rates fueled by private credit returns. Rising concerns about the quality and stability of private credit investments are prompting analysts to flag new financial system risks amid broader economic and geopolitical instability.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 10:12 AM EDT Best Dividend Stock to Buy with $5,000: Coca-Cola (KO) Offers Reliable Income April 11, 2026, 10:12 AM EDT. Investors seeking steady income can consider buying Coca-Cola (NYSE: KO) with $5,000, acquiring about 66 shares at $75.91 each. The beverage giant recently raised its quarterly dividend to $0.53, marking its 64th consecutive annual increase. This longevity highlights Coca-Cola's commitment to shareholders and dividend sustainability, driven by its strong brand and stable market position. While Coca-Cola's 10-year total return trails the broader S&P 500 index, it remains
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop